Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Deepak L. Bhatt, M.D.

Co-Author

This page shows the publications co-authored by Deepak Bhatt and Muthiah Vaduganathan.
Connection Strength

25.708
  1. Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency. J Am Coll Cardiol. 2020 Nov 24; 76(21):2517-2521.
    View in: PubMed
    Score: 0.880
  2. Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy. Eur J Heart Fail. 2021 03; 23(3):384-392.
    View in: PubMed
    Score: 0.864
  3. Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. Am J Cardiol. 2020 05 15; 125(10):1577-1581.
    View in: PubMed
    Score: 0.837
  4. Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. J Am Coll Cardiol. 2019 04 02; 73(12):1596-1598.
    View in: PubMed
    Score: 0.785
  5. Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. J Am Coll Cardiol. 2018 12 25; 72(25):3370-3372.
    View in: PubMed
    Score: 0.771
  6. The Reply. Am J Med. 2018 09; 131(9):e389-e390.
    View in: PubMed
    Score: 0.749
  7. The Reply. Am J Med. 2018 06; 131(6):e263.
    View in: PubMed
    Score: 0.741
  8. The Reply. Am J Med. 2018 06; 131(6):e267-e268.
    View in: PubMed
    Score: 0.741
  9. Baseline Blood Pressure, the 2017 ACC/AHA High Blood Pressure Guidelines, and Long-Term Cardiovascular Risk in SPRINT. Am J Med. 2018 08; 131(8):956-960.
    View in: PubMed
    Score: 0.725
  10. Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. EuroIntervention. 2018 02 02; 13(15):e1841-e1849.
    View in: PubMed
    Score: 0.725
  11. Reply: Cangrelor or Abciximab as First Choice in Cardiogenic Shock. JACC Cardiovasc Interv. 2017 12 11; 10(23):2468-2469.
    View in: PubMed
    Score: 0.717
  12. Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials. Am J Med. 2018 05; 131(5):575-577.
    View in: PubMed
    Score: 0.717
  13. Cangrelor Use in Cardiogenic Shock: A Single-Center Real-World Experience. JACC Cardiovasc Interv. 2017 08 28; 10(16):1712-1714.
    View in: PubMed
    Score: 0.703
  14. Cardiac Troponins in Chronic Kidney Disease: A Marker of Global Cardiovascular Risk. Am J Nephrol. 2017; 45(4):301-303.
    View in: PubMed
    Score: 0.678
  15. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA Cardiol. 2017 02 01; 2(2):127-135.
    View in: PubMed
    Score: 0.676
  16. Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem. Clin Gastroenterol Hepatol. 2017 05; 15(5):691-693.
    View in: PubMed
    Score: 0.673
  17. Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital. J Am Coll Cardiol. 2017 01 31; 69(4):463-464.
    View in: PubMed
    Score: 0.668
  18. Gastroprotection with proton-pump inhibitors in high-risk cardiovascular patients: who to target and for how long? Expert Opin Drug Saf. 2016 Nov; 15(11):1451-1453.
    View in: PubMed
    Score: 0.656
  19. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. Circ Cardiovasc Interv. 2016 06; 9(6).
    View in: PubMed
    Score: 0.645
  20. Elevated Troponin Levels in Stable Patients Undergoing Hemodialysis: A Red Flag or a Red Herring? Am J Nephrol. 2016; 43(3):170-2.
    View in: PubMed
    Score: 0.639
  21. Simultaneous Platelet P2Y12 and P2Y1 ADP Receptor Blockade: Are Two Better Than One? Arterioscler Thromb Vasc Biol. 2016 Mar; 36(3):427-8.
    View in: PubMed
    Score: 0.634
  22. Moving Toward Global Primordial Prevention in Cardiovascular Disease: The Heart of the Matter. J Am Coll Cardiol. 2015 Oct 06; 66(14):1535-1537.
    View in: PubMed
    Score: 0.617
  23. Heads Up! Introducing Wearable Health Technologies in Cardiology. J Invasive Cardiol. 2015 Oct; 27(10):447.
    View in: PubMed
    Score: 0.616
  24. Revisiting the Clopidogrel-Proton Pump Inhibitor Interaction: From Bench to Bedside. Circ Cardiovasc Interv. 2015 Oct; 8(10).
    View in: PubMed
    Score: 0.616
  25. Aspirin and proton-pump inhibitors: interpreting the interplay. Eur Heart J Cardiovasc Pharmacother. 2016 01; 2(1):20-2.
    View in: PubMed
    Score: 0.615
  26. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: decongesting the matter. Eur Heart J. 2015 Jun 21; 36(24):1497-8.
    View in: PubMed
    Score: 0.604
  27. Manual thrombectomy in myocardial infarction: aspiring for better. J Am Heart Assoc. 2015 Jun 15; 4(6):002201.
    View in: PubMed
    Score: 0.604
  28. Manual Thrombectomy in Myocardial Infarction: Aspiring for Better. J Am Heart Assoc. 2015; 4(6).
    View in: PubMed
    Score: 0.604
  29. Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT). Eur Heart J Cardiovasc Pharmacother. 2022 05 05; 8(3):E12-E14.
    View in: PubMed
    Score: 0.243
  30. Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States. Circ Heart Fail. 2022 03; 15(3):e009099.
    View in: PubMed
    Score: 0.237
  31. Serum Potassium and Mortality in High-Risk Patients: SPRINT. Hypertension. 2021 11; 78(5):1586-1594.
    View in: PubMed
    Score: 0.234
  32. Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States. Prog Cardiovasc Dis. 2021 Sep-Oct; 68:97-98.
    View in: PubMed
    Score: 0.233
  33. Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients. J Gen Intern Med. 2021 08; 36(8):2532-2535.
    View in: PubMed
    Score: 0.228
  34. Intensive blood pressure control appears to be effective and safe in patients with peripheral artery disease: the Systolic Blood Pressure Intervention Trial. Eur Heart J Cardiovasc Pharmacother. 2021 05 23; 7(3):e38-e40.
    View in: PubMed
    Score: 0.228
  35. Intensive vs. standard blood pressure control and vascular procedures: insights from the Systolic Blood Pressure Intervention Trial (SPRINT). Eur Heart J Cardiovasc Pharmacother. 2021 05 23; 7(3):e35-e37.
    View in: PubMed
    Score: 0.228
  36. Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. Eur Heart J Cardiovasc Pharmacother. 2020 11 01; 6(6):356-363.
    View in: PubMed
    Score: 0.219
  37. Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. J Am Coll Cardiol. 2020 Jul 21; 76(3):280-288.
    View in: PubMed
    Score: 0.213
  38. Marijuana Use in Patients With Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2020 01 28; 75(3):320-332.
    View in: PubMed
    Score: 0.208
  39. Longitudinal trajectories of hospital performance across targeted cardiovascular conditions in the USA. Eur Heart J Qual Care Clin Outcomes. 2020 01 01; 6(1):62-71.
    View in: PubMed
    Score: 0.207
  40. Left Ventricular Thrombus: Contemporary Etiologies, Treatment Strategies, and Outcomes. J Am Coll Cardiol. 2019 04 23; 73(15):2007-2009.
    View in: PubMed
    Score: 0.195
  41. Body Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the SPRINT Trial. Am J Med. 2019 07; 132(7):840-846.
    View in: PubMed
    Score: 0.194
  42. Pulse Pressure, Cardiovascular Events, and Intensive Blood-Pressure Lowering in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Med. 2019 06; 132(6):733-739.
    View in: PubMed
    Score: 0.193
  43. Thirty-Day Readmissions After Hospitalization for Hypertensive Emergency. Hypertension. 2019 01; 73(1):60-67.
    View in: PubMed
    Score: 0.193
  44. The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials: A Report of 348 Studies Registered With ClinicalTrials.gov. JACC Clin Electrophysiol. 2018 07; 4(7):944-954.
    View in: PubMed
    Score: 0.186
  45. Contemporary parenteral antiplatelet bridging strategies: a single-centre real-world experience at a tertiary care centre. EuroIntervention. 2018 06 08; 14(3):e333-e335.
    View in: PubMed
    Score: 0.186
  46. Availability and Use of Shared Data From Cardiometabolic Clinical Trials. Circulation. 2018 02 27; 137(9):938-947.
    View in: PubMed
    Score: 0.178
  47. Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). Am J Cardiol. 2017 Oct 01; 120(7):1043-1048.
    View in: PubMed
    Score: 0.174
  48. Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention. Am J Cardiol. 2017 Aug 01; 120(3):359-361.
    View in: PubMed
    Score: 0.172
  49. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2017 Jan 17; 69(2):176-185.
    View in: PubMed
    Score: 0.168
  50. Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment. J Am Coll Cardiol. 2016 08 30; 68(9):981-2.
    View in: PubMed
    Score: 0.164
  51. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. Am J Med. 2016 Sep; 129(9):1002-5.
    View in: PubMed
    Score: 0.160
  52. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. J Am Coll Cardiol. 2016 Apr 12; 67(14):1661-71.
    View in: PubMed
    Score: 0.159
  53. Prognostic significance of obstructive coronary artery disease in patients admitted with acute decompensated heart failure: the ARIC study community surveillance. Eur J Heart Fail. 2022 Jul 18.
    View in: PubMed
    Score: 0.062
  54. Optimizing Foundational Therapies in Patients With HFrEF: How Do We Translate These Findings Into Clinical Care? JACC Basic Transl Sci. 2022 May; 7(5):504-517.
    View in: PubMed
    Score: 0.060
  55. Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study. J Card Fail. 2022 08; 28(8):1267-1277.
    View in: PubMed
    Score: 0.060
  56. Guideline based eligibility for primary prevention statin therapy - Insights from the North India ST-elevation myocardial infarction registry (NORIN-STEMI). J Clin Lipidol. 2022 Mar-Apr; 16(2):227-236.
    View in: PubMed
    Score: 0.059
  57. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. J Diabetes Complications. 2022 02; 36(2):108101.
    View in: PubMed
    Score: 0.059
  58. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 10 19; 78(16):1635-1654.
    View in: PubMed
    Score: 0.059
  59. Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials. medRxiv. 2021 May 04.
    View in: PubMed
    Score: 0.057
  60. Amyloidosis and 30-Day Outcomes Among Patients With Heart Failure: A Nationwide Readmissions Database Study. JACC CardioOncol. 2020 Dec; 2(5):710-718.
    View in: PubMed
    Score: 0.055
  61. Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. Am Heart J. 2021 02; 232:105-115.
    View in: PubMed
    Score: 0.055
  62. Prognostic implications of left ventricular hypertrophy diagnosed on electrocardiogram vs echocardiography. J Clin Hypertens (Greenwich). 2020 09; 22(9):1647-1658.
    View in: PubMed
    Score: 0.054
  63. Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review. JAMA Cardiol. 2020 06 01; 5(6):714-722.
    View in: PubMed
    Score: 0.053
  64. Quantifying the Impact of Care Fragmentation on Outcomes After Transcatheter Aortic Valve Implantation. Am J Cardiol. 2020 08 01; 128:113-119.
    View in: PubMed
    Score: 0.053
  65. Performance in Federal Value-Based Programs of Hospitals Recognized by the American Heart Association and American College of Cardiology for High-Quality Heart Failure and Acute Myocardial Infarction Care. JAMA Cardiol. 2020 05 01; 5(5):515-521.
    View in: PubMed
    Score: 0.053
  66. Running thin: implications of a heparin shortage. Lancet. 2020 02 15; 395(10223):534-536.
    View in: PubMed
    Score: 0.052
  67. Design and rationale of the North Indian ST-Segment Elevation Myocardial Infarction Registry: A prospective cohort study. Clin Cardiol. 2019 Dec; 42(12):1140-1146.
    View in: PubMed
    Score: 0.051
  68. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet. 2019 05 25; 393(10186):2155-2167.
    View in: PubMed
    Score: 0.050
  69. Wake Forest University long-term follow-up of type 2 myocardial infarction: The Wake-Up T2MI Registry. Clin Cardiol. 2019 Jun; 42(6):592-604.
    View in: PubMed
    Score: 0.049
  70. Association of the New Peer Group-Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. JAMA Netw Open. 2019 04 05; 2(4):e192987.
    View in: PubMed
    Score: 0.049
  71. Open Access Publishing and Subsequent Citations Among Articles in Major Cardiovascular Journals. Am J Med. 2019 09; 132(9):1103-1105.
    View in: PubMed
    Score: 0.049
  72. Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction. Circulation. 2019 02 19; 139(8):1047-1056.
    View in: PubMed
    Score: 0.049
  73. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. Resuscitation. 2019 04; 137:205-212.
    View in: PubMed
    Score: 0.049
  74. Characterizing High-Performing Articles by Altmetric Score in Major Cardiovascular Journals. JAMA Cardiol. 2018 12 01; 3(12):1249-1251.
    View in: PubMed
    Score: 0.048
  75. Fifteen-Year Trends in Management and Outcomes of Non-ST-Segment-Elevation Myocardial Infarction Among Black and White Patients: The ARIC Community Surveillance Study, 2000-2014. J Am Heart Assoc. 2018 10 02; 7(19):e010203.
    View in: PubMed
    Score: 0.047
  76. Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment. JAMA Cardiol. 2018 07 01; 3(7):642-649.
    View in: PubMed
    Score: 0.047
  77. Reply: Intersection of fasting plasma glucose, adverse cardiac remodeling, and clinical outcomes. Int J Cardiol. 2018 02 01; 252:214-215.
    View in: PubMed
    Score: 0.045
  78. Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. Eur J Prev Cardiol. 2017 10; 24(15):1648-1659.
    View in: PubMed
    Score: 0.043
  79. Prognostic implications of fasting plasma glucose in subjects with echocardiographic abnormalities. Int J Cardiol. 2017 Aug 15; 241:423-429.
    View in: PubMed
    Score: 0.042
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.